Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience
暂无分享,去创建一个
[1] M. Nour,et al. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world , 2022, Psychopharmacology.
[2] M. Bielecki,et al. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences , 2022, Journal of psychopharmacology.
[3] R. Carhart-Harris,et al. Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience , 2022, Journal of psychopharmacology.
[4] Chris Letheby. The mechanisms of psychedelic therapy , 2021, Philosophy of Psychedelics.
[5] J. Woolley,et al. Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis , 2021 .
[6] Alan K. Davis,et al. Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. , 2021, ACS pharmacology & translational science.
[7] D. E. Olson. The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. , 2020, ACS pharmacology & translational science.
[8] R. Griffiths,et al. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. , 2020, ACS pharmacology & translational science.
[9] Karen Zilberstein. Neoliberalism in clinical social work practice: the benefits and limitations of embedded ideals of individualism and resiliency , 2021 .
[10] Brian T Anderson,et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study , 2020, EClinicalMedicine.
[11] A. Niemeijer,et al. Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies , 2020, CNS Drugs.
[12] M. van Elk,et al. Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism , 2020, Psychopharmacology.
[13] Chris Letheby,et al. Psychedelic experience and the narrative self: An exploratory qualitative study , 2020 .
[14] R. Watts,et al. The use of the psychological flexibility model to support psychedelic assisted therapy , 2020 .
[15] S. Hayes,et al. The centrality of sense of self in psychological flexibility processes: What the neurobiological and psychological correlates of psychedelics suggest , 2020 .
[16] Alan K. Davis,et al. Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment , 2019, Psychopharmacology.
[17] R. Carhart-Harris,et al. From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner , 2019, International journal of environmental research and public health.
[18] F. Vollenweider,et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat , 2019, Scientific Reports.
[19] E. Argento,et al. Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. , 2019, Drug and alcohol review.
[20] Jacob S. Aday,et al. 2018: A watershed year for psychedelic science , 2019, Drug Science, Policy and Law.
[21] J. Ramaekers,et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms , 2019, Psychopharmacology.
[22] A. Greig,et al. Towards a Better Understanding of the Relationship between Individual’s Self-Reported Connection to Nature, Personal Well-Being and Environmental Awareness , 2019, Sustainability.
[23] G. Maruyama,et al. Replication and extension of a model predicting response to psilocybin , 2019, Psychopharmacology.
[24] J. Haro,et al. Act-Belong-Commit Indicators Promote Mental Health and Wellbeing among Irish Older Adults. , 2018, American journal of health behavior.
[25] N. Broers,et al. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution , 2018, Psychopharmacology.
[26] A. Garcia-Romeu,et al. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions , 2018, International review of psychiatry.
[27] P. Hendricks. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy , 2018, International review of psychiatry.
[28] Matthew W. Johnson,et al. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts , 2018, Journal of psychopharmacology.
[29] G. Noblit. Meta-Ethnography , 2018, Oxford Scholarship Online.
[30] Elizabeth M. Nielson,et al. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions , 2018, Front. Pharmacol..
[31] Samantha K. Podrebarac,et al. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder , 2018, Front. Pharmacol..
[32] Robin L Carhart-Harris,et al. Psychedelics and the essential importance of context , 2018, Journal of psychopharmacology.
[33] David J. Nutt,et al. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression , 2018, Front. Pharmacol..
[34] K. Alper,et al. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes , 2018, The American journal of drug and alcohol abuse.
[35] Frederick S Barrett,et al. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. , 2018, Current topics in behavioral neurosciences.
[36] D. Nutt,et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up , 2017, Psychopharmacology.
[37] Matthias Forstmann,et al. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness , 2017, Journal of psychopharmacology.
[38] David J. Nutt,et al. Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression , 2017 .
[39] Raphaël Millière,et al. Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution , 2017, Frontiers in human neuroscience.
[40] H. Friedman,et al. Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis , 2017 .
[41] Matthew W. Johnson,et al. Long-term follow-up of psilocybin-facilitated smoking cessation , 2017, The American journal of drug and alcohol abuse.
[42] Matthew W. Johnson,et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.
[43] P. Garrett. Questioning Tales of ‘Ordinary Magic’: ‘Resilience’ and Neo-Liberal Reasoning , 2016 .
[44] James Rucker,et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.
[45] M. Nour,et al. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI) , 2016, Front. Hum. Neurosci..
[46] Matthew W. Johnson,et al. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin , 2015, Journal of psychopharmacology.
[47] Kate Cavanagh,et al. How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. , 2015, Clinical psychology review.
[48] M. Lalayants,et al. Loneliness and Depression or Depression-Related Factors Among Child Welfare-Involved Adolescent Females , 2015 .
[49] J. Gallinat,et al. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? , 2015, Journal of psychopharmacology.
[50] R. Strassman,et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.
[51] Matthew W. Johnson,et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.
[52] Peter J Hellyer,et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs , 2014, Front. Hum. Neurosci..
[53] Aaron Smith,et al. 6% of online adults are reddit users , 2013 .
[54] G. Martin,et al. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. , 2013, Current drug abuse reviews.
[55] Matthew W. Johnson,et al. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness , 2011, Journal of psychopharmacology.
[56] Matthew W. Johnson,et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects , 2011, Psychopharmacology.
[57] A. Piper,et al. A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?1 , 2011, Economic Botany.
[58] C. Grob,et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.
[59] Michael Kometer,et al. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.
[60] F. Vollenweider,et al. Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) , 2010, PloS one.
[61] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[62] S. Krippner,et al. Changes in Spirituality Among Ayahuasca Ceremony Novice Participants , 2009, Journal of psychoactive drugs.
[63] E. Goode. moral panics and disproportionality: the case of LSD use in the sixties , 2008 .
[64] R. Griffiths,et al. Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.
[65] R. Griffiths,et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.
[66] L. Hawkley,et al. Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. , 2006, Psychology and aging.
[67] S. Peroutka,et al. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex , 2004, Psychopharmacology.
[68] Nilly Mor,et al. Self-focused attention and negative affect: a meta-analysis. , 2002, Psychological bulletin.
[69] N. Goodman. The Serotonergic System and Mysticism: Could LSD and the Nondrug-Induced Mystical Experience Share Common Neural Mechanisms? , 2002, Journal of psychoactive drugs.
[70] A Dittrich,et al. The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans , 1998, Pharmacopsychiatry.
[71] R A Williams,et al. Sense of belonging and indicators of social and psychological functioning. , 1996, Archives of psychiatric nursing.
[72] I. Åkerlind,et al. Loneliness and alcohol abuse: a review of evidences of an interplay. , 1992, Social science & medicine.
[73] R. Glennon,et al. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.
[74] R. Mogar,et al. Peak Experiences: Investigation of Their Relationship to Psychedelic Therapy and Self-Actualization , 1967 .
[75] G. H. Litwin,et al. REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT , 1963, The Journal of nervous and mental disease.